CLPBY (CLPBY) Stock Price & Analysis
CLPBY (CLPBY) rose 2.82% to USD 6.19 as of July 25, 2026 at 03:07 UTC, according to Nexqual real-time market data.
CLPBY last closed at USD 6.02; the session ranged USD 6.11–6.19 on volume of 47,681 shares. Market capitalization is $13.95B, with a 52-week range of USD 5.64–10.03 (PNK). Source: Nexqual, July 25, 2026 at 03:07 UTC.
Key Statistics (as of July 25, 2026 at 03:07 UTC)
| Price | USD 6.19 |
|---|---|
| Change | ▲ 2.82% (up) |
| Previous Close | USD 6.02 |
| Open | USD 6.11 |
| Day Range | USD 6.11 – 6.19 |
| 52-Week Range | USD 5.64 – 10.03 |
| Volume | 47,681 shares |
| Market Cap | $13.95B |
| Exchange | PNK |
Technical Analysis (CLPBY)
Nexqual's technical model rates CLPBY "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 03:07 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 51.98 (neutral) |
| vs SMA50 | Above (USD 6.09) |
| MACD | 0.06 (positive) |
Analyst Ratings (CLPBY)
Wall Street analysts rate CLPBY "Buy" based on 4 analysts, with a mean price target of USD 8.3 (range USD 6.5–12.2), per Nexqual as of July 25, 2026 at 03:07 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.3 |
| High Target | USD 12.2 |
| Low Target | USD 6.5 |
| Buy / Hold / Sell | 1 / 3 / 0 |
Earnings (CLPBY)
| EPS Estimate | USD 0.09 |
|---|---|
| Revenue Estimate | $7.27B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0 vs est 0.09 ▼ miss |
| 2025-12-31 | USD 0.1 vs est 0.1 ▲ beat |
| 2025-09-30 | USD 0.07 vs est 0.11 ▼ miss |
| 2025-06-30 | USD 0.08 vs est 0.09 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Financials & Fundamentals (CLPBY)
| Total Revenue | $28.05B |
|---|---|
| Revenue Growth (YoY) | +2.20% |
| Gross Margin | +67.46% |
| Operating Margin | +25.69% |
| Profit Margin | +7.51% |
| ROE | +14.14% |
| Debt / Equity | 188.65 |
| Current Ratio | 1.75 |
| Total Cash | $1.07B |
| Total Debt | $24.23B |
| Free Cash Flow | $4.20B |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Financial Health Score (CLPBY)
Nexqual rates CLPBY's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:07 UTC.
| Growth | Mixed — Revenue +3.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 67%, operating 26% |
| Balance Sheet | Weak — $1.07B cash vs $24.2B debt |
| Cash Flow | Strong — FCF $4.20B, 15% margin |
| Efficiency | Mixed — ROE 14%, ROA 9.9% |
Ownership (CLPBY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 2.07B |
| Float | 1.45B |
Source: Nexqual, July 25, 2026 at 03:07 UTC.
Leadership (CLPBY)
CLPBY is led by Gavin Wood (age 54), President & CEO, per Nexqual as of July 25, 2026 at 03:07 UTC.
| President & CEO | Gavin Wood (age 54) |
|---|---|
| Executive VP & CFO | Anders Lonning-Skovgaard (age 53) |
| Executive Vice President of Global Operations | Allan Rasmussen (age 58) |
| Executive Vice President of Chronic Care | Nicolai Buhl Andersen (age 56) |
| Senior Controller & Employees Representative Director | Thomas Barfod (age 55) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 22 | ▼ 1.57% |
| ESLOY | EssilorLuxottica | USD 92.54 | ▼ 1.43% |
| FSNUY | Fresenius SE & Co. KGaA | USD 12.48 | ▲ 0.16% |
| NVZMY | NOVONESIS A S | USD 62.52 | ▼ 3.41% |
| HOCPY | Hoya Corp. | USD 149.26 | ▼ 3.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:07 UTC. This page is informational and not investment advice.